Neurocrine Biosciences (NBIX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX)

NBIX 143.95

-0.9%

3:11 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Laurens who wrote (119)	3/3/1999 6:41:00 PM
From: Lel H	Read Replies (1) of 1834

I think the AHP news helped support NBIX a little bit today. The DHEA trial failure, regardless of whether it was thought to be a longshot or not, does represent a failure of their most advanced(?) product in their pipeline. Without the AHP deal, there might have been more downside today. The AHP deal sounds good, but the $78 million number that caught my eye on the press release is by no means a sure thing. NBIX has to meet developmental milestones in order to see a lot of that money. But, it does provide for research expenses, which is important as they delve deeper into this avenue of research. We're probably still a long way from any INDs that might come from this collaboration. I guess we'll just have to be more patient.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next